cTAPcTAPcTAPcTAP
  • WHAT WE DO
  • HOW WE DO IT
    • Our Leadership
    • OUR SCIENTIFIC ADVISORS
    • Our Approach
  • OUR PROGRAMS
    • cTAP DUCHENNE
    • What’s Next
  • OUR IMPACT
    • Publications
    • Abstracts
    • News & Press
    • Presentations
  • PARTNER WITH US
    • Patient Organizations
    • Scientific Leaders & Researchers
    • Industry
  • CONTACT

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

Home / Blog / Publications / Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy
A prognostic model for 1 year change in 4SC

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials

Craig M. McDonald, MD, Gautam Sajeev, ScD, Zhiwen Yao, BA, Erin McDonnell, MS, Gary Elfring, MS, Marcio Souza, PharmD, MBA, Stuart W. Peltz, PhD, Basil T. Darras, MD, Perry B. Shieh, MD, PhD, David A. Cox, PhD, John Landry, MMath, James Signorovitch, PhD, and for the ACT DMD Study Group and the Tadalafil DMD Study Group. Muscle Nerve. 2020 Jan; 61(1): 26–35.

View the PDF

10
Jan 2020
By SCsbox3AdminPublicationsComments Off on Deflazacort vs prednisone treatment for Duchenne muscular dystrophy

Read the latest

  • Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
  • Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials
  • New study may help more DMD patients be included in clinical trials
  • Press release: cTAP Study Indicates DMD Clinical Trial Enrollment Criteria Should Expand Beyond Ambulatory Status
  • Minimal detectable changes in functional measures in Duchenne muscular dystrophy: a study of multiple centers, networks and trial arms

COLLABORATIVE TRAJECTORY
ANALYSIS PROJECT

Cambridge Innovative Center
One Broadway, Cambridge, MA 02142

T: 617-555-5555
E: info@ctap-nmd.org

Terms & Conditions
Privacy Policy

© 2025 Collaborative Trajectory Analysis Project. All rights reserved.

  • WHAT WE DO
  • HOW WE DO IT
    • Our Leadership
    • OUR SCIENTIFIC ADVISORS
    • Our Approach
  • OUR PROGRAMS
    • cTAP DUCHENNE
    • What’s Next
  • OUR IMPACT
    • Publications
    • Abstracts
    • News & Press
    • Presentations
  • PARTNER WITH US
    • Patient Organizations
    • Scientific Leaders & Researchers
    • Industry
  • CONTACT

Terms and Conditions - Privacy Policy